Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome
| Status: | Recruiting |
|---|---|
| Conditions: | Smoking Cessation, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2008 |
Assess the role of a nicotine antagonist in helping patients presenting to hospital with
acute coronary syndrome to stop smoking.
acute coronary syndrome to stop smoking.
Inclusion Criteria:
- active smokers presenting to hospital with an acute coronary syndrome
Exclusion Criteria:
- patients with an acute coronary syndrome who are not active smokers
We found this trial at
1
site
Newark Beth Israel Medical Center Newark Beth Israel Medical Center, a regional care, teaching hospital...
Click here to add this to my saved trials
